研究者業績

小林 欣夫

コバヤシ ヨシオ  (Yoshio Kobayashi)

基本情報

所属
千葉大学 大学院医学研究院循環器内科学 教授
学位
博士(医学)(千葉大学)

J-GLOBAL ID
200901031812437900
researchmap会員ID
5000068706

論文

 880
  • 佐野 元洋, 岡田 将, 眞嶋 朋子, 小林 欣夫
    心臓リハビリテーション 27(1) 45-49 2021年3月  
    【目的】訪問看護における心不全管理に関する現状を学習方法とニーズの観点から明らかにすることである。【方法】千葉県内にある訪問看護ステーションへ郵送でアンケート用紙を送付した。【結果】最終的に返送のあった80通(回収率37%)を分析した。多くの訪問看護師が自己学習と外部研修に参加をして心不全管理の学習をしていたが、心不全の基礎的な知識に加え、地域連携や事例の共有、活動量や食事の具体的な目安と指標のような研修のニーズ、在宅生活を見える化するツールの使用などのニーズが挙げられた。【結論】多くの訪問看護師が外部の研修に参加しているものの、ニーズを十分に満たす研修が開催されていない可能性がある。訪問看護における心不全管理の質向上に向けて、多忙な職場環境においても参加しやすい形式の検討および迅速に現場に活用できるニーズに則した研修内容の検討の必要性が示唆された。(著者抄録)
  • 岡田 将, 梅野 福太郎, 山崎 恵一, 岩花 東吾, 加藤 央隼, 佐野 元洋, 東辻 朝彦, 眞嶋 朋子, 小林 欣夫
    日本循環器学会学術集会抄録集 85回 SY24-5 2021年3月  
  • Yuki Deguchi, Yuichi Saito, Motohiro Nakao, Hirokazu Shiraishi, Naoya Sakamoto, Satoru Kobayashi, Yoshio Kobayashi
    Heart and vessels 36(3) 315-320 2021年3月  
    Acute kidney injury usually assessed within 48 h after percutaneous coronary intervention (PCI) is associated with poor clinical outcomes, and persistent kidney damage is also strongly related to long-term mortality. However, little is known about longitudinal renal function change from a very early period to long-term follow-up after PCI. A total of 327 patients with stable coronary artery disease underwent elective PCI. Renal function was assessed with serum creatinine levels and estimated glomerular filtration rate (eGFR) at baseline, 1 day after PCI, at 1 year and at the latest follow-up. Kidney injury was defined as an increase in creatinine levels ≥ 0.3 mg/dl or ≥ 50% from baseline at each timepoint. Major adverse cardiovascular events (MACE) was defined as a composite of death, myocardial infarction, and stroke. eGFR was significantly increased 1 day after PCI, while it was progressively decreased at 1-year and long-term follow-up (median 28 months). Overall, eGFR was declined by - 2.3 ml/min/1.73 m2 per year. Only one (0.3%) patient developed kidney injury 1 day after PCI, whereas kidney injury at 1-year and long-term follow-up was observed in 15 (4.6%) and 27 (8.3%). During the follow-up period, 23 (7.0%) patients had MACE. The incidence of subsequent MACE was significantly higher in patients with kidney injury at 1 year than those without. In conclusion, kidney injury within 24 h after elective PCI was rarely observed. eGFR was progressively decreased over time, and mid-term kidney injury at 1 year was associated with future MACE.
  • Kazuya Tateishi, Yuichi Saito, Hideki Kitahara, Hiroyuki Takaoka, Yusuke Kondo, Takashi Nakayama, Yoshihide Fujimoto, Yoshio Kobayashi
    Heart and vessels 36(3) 321-329 2021年3月  
    BACKGROUND: Vasospastic angina (VSA) reportedly accounts for one form of sudden cardiac arrest (SCA). Intracoronary acetylcholine (ACh) testing is useful for diagnosing VSA although invasive provocation testing after SCA is a clinical challenge. In addition, even if the ACh test is positive, any causal relationship between VSA and SCA is often unclear because patients with VSA may have other underlying cardiac disorders. METHODS: A total of 20 patients without overt structural heart disease who had been fully resuscitated from SCA were included. All patients underwent the ACh provocation test and scrutiny such as cardiac computed tomography or magnetic resonance imaging. Patients were followed up for all-cause death or recurrent SCA including appropriate implantable cardioverter defibrillator therapy. RESULTS: An ACh provocation test was performed 20 ± 17 days after cardiac arrest. Fifteen out of 20 (75.0%) patients had a positive ACh test and 2 (10.0%) had adverse events such as ventricular tachycardia and transient cardiogenic shock during the test. In patients with a positive ACh test, 6 of 15 (40.0%) patients had other overlapping cardiac disorders such as long QT syndrome, Brugada syndrome, cardiac sarcoidosis, myocarditis, or cardiomyopathy. Long-term prognosis was not different regardless of a positive ACh test or the presence of other cardiac disorders overlapping with VSA. CONCLUSIONS: Three-quarters of the patients who had been resuscitated from SCA had a positive ACh test. Further examinations revealed other overlapping cardiac disorders in addition to VSA in 40% of patients with a positive ACh test.
  • Takatsugu Kajiyama, Yusuke Kondo, Masahiro Nakano, Kazuo Miyazawa, Miyo Nakano, Tomohiko Hayashi, Ryo Ito, Haruhiro Takahira, Mari Kitagawa, Yoshio Kobayashi
    Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing 60(2) 239-245 2021年3月  査読有り
    BACKGROUND: Leadless pacemakers are an effective treatment for bradycardia. However, some cases exhibit pericardial effusions, presumably associated with device implantations on the right ventricular free-wall. The present study was carried out to find the ECG features during ventricular pacing with a Micra, which enabled distinguishing free-wall implantations from septal implantations without using imaging modalities. METHODS: Thirty-one consecutive patients who received Micra implantations in our facility were enrolled. The location of the device in the right ventricle was evaluated using echocardiography or computed tomography in order to determine whether the device was implanted on the septum (Sep group), apex (Apex group), or free-wall (FW group). The differences in the 12-lead ECG during ventricular pacing by the Micra were analyzed between the Sep and FW groups. RESULTS: The body of the Micra was clearly identifiable in 22 patients. The location of the device was classified into Sep in 12 patients, Apex in 4, and FW in 6. The mean age was highest in the FW and lowest in the Sep group (82.7 ± 6.6 vs. 72.8 ± 8.7 years, p = 0.027). The peak deflection index (PDI) was significantly larger in the FW group than Sep/Apex group in lead V1 (Sep: 0.505 ± 0.010, Apex: 0.402 ± 0.052, FW: 0.617 ± 0.043, p = 0.004) and lead V2 (Sep: 0.450 ± 0.066, Apex: 0.409 ± 0.037, FW: 0.521 ± 0.030, p = 0.011), whereas there was no difference in the QRS duration, transitional zone, and QRS notching. CONCLUSION: The PDI in V1 could be useful for predicting implantations of Micra devices on the free-wall and may potentially stratify the risk of postprocedural pericardial effusions.
  • Ryohei Ono, Takatsugu Kajiyama, Ryo Ito, Yoshio Kobayashi
    QJM : monthly journal of the Association of Physicians 2021年2月12日  
  • 小野 亮平, 岩花 東吾, 加藤 央隼, 岡田 将, 小林 欣夫
    日本内科学会雑誌 110(臨増) 157-157 2021年2月  
  • Masayuki Ishimura, Masashi Yamamoto, Yoshiharu Himi, Yoshio Kobayashi
    Heart rhythm 18(2) 323-324 2021年2月  
  • Ryohei Ono, Takatsugu Kajiyama, Yoshio Kobayashi
    BMJ case reports 14(2) 2021年2月1日  
  • Yuichi Saito, Takeshi Nishi, Shinichi Wakabayashi, Yuji Ohno, Hideki Kitahara, Noritaka Ariyoshi, Yoshio Kobayashi
    Journal of Atherosclerosis and Thrombosis 2021年  
  • Togo Iwahana, Yuichi Saito, Sho Okada, Hirotoshi Kato, Ryohei Ono, Yoshio Kobayashi
    PloS one 16(11) e0259485 2021年  
    Esaxerenone, a mineralocorticoid receptor blocker (MRB), is a new antihypertensive agent. However, esaxerenone-related data with respect to hypertension with heart failure are limited. We investigated the safety and efficacy of esaxerenone in hypertensive patients with heart failure with reduced ejection fraction (HFrEF). Hypertensive patients with HFrEF treated with esaxerenone were retrospectively analyzed at two timepoints (short-term: 35±15 days; mid-term: 167±45 days). Adverse events including hyperkalemia (K+ >5.5 mEq/L), worsening renal function (WRF; estimated glomerular filtration rate (eGFR) reduction by ≥20%), and hypotension (systolic blood pressure <90 mmHg) were evaluated. eGFR and K+, serum creatinine, and brain natriuretic peptide (BNP) levels at baseline, short-term, and mid-term assessments were compared. Patients administered esaxerenone as their first MRB (first-MRB cohort) and those who converted from another MRB (conversion cohort) were separately analyzed. There were 50 (56±10 years old, 26% female) patients. At the short-term assessment, hyperkalemia or hypotension was not observed at a dose of 2.0±0.9 mg/day. Seven patients (14%) showed WRF. K+ was slightly elevated (4.12±0.41 to 4.25±0.39 mmol/L, p = 0.07) and eGFR was significantly reduced (66.9±19.6 mL/min/1.73 m2 to 62.4±19.7 mL/min/1.73 m2, p = 0.006). In the conversion cohort, significant changes in K+ and eGFR from baseline were not observed at the short-term assessment. BNP levels were consistently improved regardless of the cohorts (first-MRB cohort, 310 [110-370] pg/mL to 137 [47-152] pg/mL, p = 0.001; conversion cohort, 181 [30-203] pg/mL to 108 [26-146] pg/mL, p = 0.028). At the mid-term assessment, there were no significant changes in K+ and eGFR compared with the short-term assessment. In conclusion, esaxerenone was safe for hypertensive patients with HFrEF. Hyperkalemia and hypotension were rarely noted, while eGFR was marginally reduced. Moreover, esaxerenone might be beneficial for HFrEF in terms of BNP level reduction.
  • Kenichi Sakakura, Yoshiaki Ito, Yoshisato Shibata, Atsunori Okamura, Yoshifumi Kashima, Shigeru Nakamura, Yuji Hamazaki, Junya Ako, Hiroyoshi Yokoi, Yoshio Kobayashi, Yuji Ikari
    Cardiovascular intervention and therapeutics 36(1) 1-18 2021年1月  
    Rotational atherectomy (RA) has been widely used for percutaneous coronary intervention (PCI) to severely calcified lesions. As compared to other countries, RA in Japan has uniquely developed with the aid of greater usage of intravascular imaging devices such as intravascular ultrasound (IVUS) or optical coherence tomography (OCT). IVUS has been used to understand the guidewire bias and to decide appropriate burr sizes during RA, whereas OCT can also provide the thickness of calcification. Owing to such abundant experiences, Japanese RA operators modified RA techniques and reported unique evidences regarding RA. The Task Force on Rotational Atherectomy of the J apanese Association of Cardiovascular Intervention and Therapeutics (CVIT) has now proposed the expert consensus document to summarize the contemporary techniques and evidences regarding RA.
  • Yuichi Saito, Yoshio Kobayashi
    Cardiovascular intervention and therapeutics 36(1) 20-22 2021年1月  
    Percutaneous coronary intervention has become a standard-of-care procedure in patients with acute and chronic coronary syndromes, in which coronary stent technology is commonly used. In this mini-review article, we summarize the characteristics of contemporary coronary drug-eluting and coated stents.
  • Kenichi Sakakura, Yoshiaki Ito, Yoshisato Shibata, Atsunori Okamura, Yoshifumi Kashima, Shigeru Nakamura, Yuji Hamazaki, Junya Ako, Hiroyoshi Yokoi, Yoshio Kobayashi, Yuji Ikari
    Cardiovascular intervention and therapeutics 36(1) 19-19 2021年1月  
  • Masayuki Ishimura, Masashi Yamamoto, Yoshiharu Himi, Yoshio Kobayashi
    HeartRhythm case reports 7(1) 34-38 2021年1月  
  • Masato Kanda, Kazuya Tateishi, Atsushi Nakagomi, Togo Iwahana, Sho Okada, Hiroyo Kuwabara, Yoshio Kobayashi, Takahiro Inoue
    PloS one 16(5) e0251505 2021年  
    The management of acute decompensated heart failure often requires intensive care. However, the effects of early intensive care unit/coronary care unit admission on activities of daily living (ADL) in acute decompensated heart failure patients have not been precisely evaluated. Thus, we retrospectively assessed the association between early intensive care unit admission and post-discharge ADL performance in these patients. Acute decompensated heart failure patients (New York Heart Association I-III) admitted on emergency between April 1, 2014, and December 31, 2018, were selected from the Diagnosis Procedure Combination database and divided into intensive care unit/coronary care unit (ICU) and general ward (GW) groups according to the hospitalization type on admission day 1. The propensity score was calculated to create matched cohorts where admission style (intensive care unit/coronary care unit admission) was independent of measured baseline confounding factors, including ADL at admission. The primary outcome was ADL performance level at discharge (post-ADL) defined according to the Barthel index. Secondary outcomes included length of stay and total hospitalization cost (expense). Overall, 12231 patients were eligible, and propensity score matching created 2985 pairs. After matching, post-ADL was significantly higher in the ICU group than in the GW group [mean (standard deviation), GW vs. ICU: 71.5 (35.3) vs. 78.2 (31.2) points, P<0.001; mean difference: 6.7 (95% confidence interval, 5.1-8.4) points]. After matching, length of stay was significantly shorter and expenses were significantly higher in the ICU group than in the GW group. Stratified analysis showed that the patients with low ADL at admission (Barthel index score <60) were the most benefited from early intensive care unit/coronary care unit admission. Thus, early intensive care unit/coronary care unit admission was associated with improved post-ADL in patients with emergency acute decompensated heart failure admission.
  • Miyo Nakano, Yusuke Kondo, Masahiro Nakano, Takatsugu Kajiyama, Kazuo Miyazawa, Tomohiko Hayashi, Ryo Ito, Haruhiro Takahira, Yoshio Kobayashi
    Heart and vessels 36(1) 99-104 2021年1月  査読有り
    Previous studies have shown that the sudden cardiac death (SCD) prediction model proposed by the 2014 European Society of Cardiology (ESC) guideline (5-Year Risk-SCD) was validated in European patients with hypertrophic cardiomyopathy (HCM). However, there are limited data on Asian patients with HCM. We assessed the validity of the estimated 5-Year Risk-SCD in Japanese HCM patients with an implantable cardioverter-defibrillator (ICD) using the2014 ESC guidelines. We retrospectively examined data of 492 consecutive Japanese patients with an ICD. Sixty-two Japanese HCM patients with an ICD were enrolled in this study, and 50 patients (81%) were followed up for ≥ 5 years. We analyzed the characteristics and outcomes of these 50 patients. We investigated the incidence of appropriate ICD therapy as categorized by the ESC guideline and compared the 5-Year Risk-SCD with the 5-year rate of appropriate shock therapies. Based on the 2012 Japanese Circulation Society guideline and the 2011guidelines of the American Heart Association and American College of Cardiology Foundation, 10 and 40 patients met classes I and IIa of the ICD recommendation, respectively. However, only 18 (36%) patients were classified into class I or IIa of the ESC guideline. Among 50 patients followed up for ≥ 5 years after ICD implantation, the incidences of appropriate ICD therapies for classes I, IIa, IIb, and III indications based on the 2014 ESC guideline were 50%, 38%, 17%, and 0%, respectively. Risk stratification for SCD using 5-Year Risk-SCD is valid in Japanese HCM patients with an ICD, and the 2014 ESC guideline might be useful for the indication of ICD implantation in Japan.
  • Ryohei Ono, Ken Kato, Yoshio Kobayashi
    Postgraduate medical journal 2020年12月30日  
  • Ryohei Ono, Sho Okada, Mari Kitagawa, Hiroyuki Takaoka, Hideyuki Miyauchi, Yoshio Kobayashi
    BMJ case reports 13(12) 2020年12月22日  
    Coronary artery fistulas are abnormal vascular conduits, rarely related to atrioventricular conduction abnormalities. We report the case of a 52-year-old woman who presented with dyspnoea on exertion. Her ECG revealed advanced atrioventricular block and left bundle branch block. CT scans confirmed two fistulas, from the conus branch of right coronary artery and from the left anterior descending coronary artery, into the pulmonary artery. The patient underwent pacemaker implantation. To date, only nine patients with different degrees of heart blocks associated with coronary artery fistulas have been reported. Herein, we review and summarise previously reported cases of different degrees of heart blocks associated with coronary artery fistulas.
  • Li S, Yoshida Y, Kobayashi E, Kubota M, Matsutani T, Mine S, Machida T, Wada T, Aotsuka A, Maezawa Y, Takemoto M, Yokote K, Kobayashi Y, Kitamura K, Hiwasa T
    2020年12月  
  • 仲野 美代, 近藤 祐介, 中野 正博, 梶山 貴嗣, 林 智彦, 伊藤 竜, 高平 青洋, 小林 欣夫
    心臓 52(Suppl.1) 217-221 2020年12月  
    背景:肥大型心筋症(HCM)患者では心臓突然死のリスクが高く、植込み型除細動器(ICD)による治療が広く行われている。心尖部肥大型心筋症(Apical HCM)の予後を検討した報告は少ない。目的:Apical HCMとその他のHCM患者のICD植え込み症例において、予後に差があるかを調べることである。方法:当院のデータベースより2006年10月から2016年7月までにICD植え込み術を施行しているHCM症例を抽出した。Apical HCMとその他のHCM患者に分けて、患者背景、採血データ、診断時の左室駆出率、最大左室壁厚、ICDの適切作動率、心疾患による入院の有無、死亡等について解析を行い、比較した。結果:2006年10月〜2016年7月にICD植え込み術を施行したHCM患者は53例(平均年齢67±15歳、男性45例(85%)、一次予防46例(87%)、フォローアップ期間85±25ヵ月、診断時左室駆出率57±12%)であり、Apical HCMは13例、その他のHCMは40例であった。2群間で年齢や性別、左室駆出率など患者背景において、有意差は認めなかった。イベントについては、Apical HCM患者はICD適切作動を13症例中5例(38%)認め、40症例中4例(10%)であったその他のHCM患者より、ICD適切作動が有意に多かった。また、2群間で心不全入院や死亡率に有意差は認めなかった。結語:ICD植え込み術後のHCM症例において、Apical HCMは、その他のHCM症例と比較し、ICD適切作動が有意に多かった。しかし、心不全による入院や死亡については、Apical HCMとその他のHCMでは有意差を認めなかった。(著者抄録)
  • Shozo Sueda, Tetsuji Shinohara, Naohiko Takahashi, Junya Shite, Toshihiro Shoji, Masaharu Akao, Yoshiyuki Kijima, Tohru Masuyama, Tsuyoshi Miyaji, Katsuhito Yamamoto, Yoshihiro Iwasaki, Ritsu Yoshida, Shigeru Nakamura, Yutaka Ogino, Kazuo Kimura, Masahiro Sasai, Hiroshi Suzuki, Tetsuzo Wakatsuki, Hiroshi Asajima, Hiroki Teragawa, Tetsunori Ishikawa, Kazuo Kitamura, Tsuyoshi Oda, Takashi Nakayama, Yoshio Kobayashi, Daisuke Sunada, Masaru Yamaki, Fumie Nishizaki, Yasushi Tomita, Kazuo Usuda, Hiroyuki Fujinaga, Shoichi Kuramitsu, Kenji Andou, Takahiko Kiyooka, Kazushige Kadota, Yoshinao Ishii, Hayato Ohtani, Yuichirou Maekawa, Eiji Taguchi, Kouichi Nakao, Nobuaki Kobayashi, Yoshihiko Seino, Hitoshi Nakagawa, Yoshihiko Saito, Issei Komuro, Yasuhiro Sasaki, Shuntarou Ikeda, Osamu Yamaguchi, Akiyoshi Kakutani, Takahiro Imanaka, Masaharu Ishihara, Masanobu Ishii, Koichi Kaikita, Kenichi Tsujita
    Heart and vessels 35(12) 1640-1649 2020年12月  
    OBJECTIVES: We investigated the medical or mechanical therapy, and the present knowledge of Japanese cardiologists about aborted sudden cardiac death (ASCD) due to coronary spasm. METHODS: A questionnaire was developed regarding the number of cases of ASCD, implantable cardioverter-defibrillator (ICD), and medical therapy in ASCD patients due to coronary spasm. The questionnaire was sent to the Japanese general institutions at random in 204 cardiology hospitals. RESULTS: The completed surveys were returned from 34 hospitals, giving a response rate of 16.7%. All SCD during the 5 years was observed in 5726 patients. SCD possibly due to coronary spasm was found in 808 patients (14.0%) and ASCD due to coronary spasm was observed in 169 patients (20.9%). In 169 patients with ASCD due to coronary spasm, one or two coronary vasodilators was administered in two-thirds of patients [113 patients (66.9%)], while more than 3 coronary vasodilators were found in 56 patients (33.1%). ICD was implanted in 117 patients with ASCD due to coronary spasm among these periods including 35 cases with subcutaneous ICD. Majority of cause of ASCD was ventricular fibrillation, whereas pulseless electrical activity was observed in 18 patients and complete atrioventricular block was recognized in 7 patients. Mean coronary vasodilator number in ASCD patients with ICD was significantly lower than that in those without ICD (2.1 ± 0.9 vs. 2.6 ± 1.0, p < 0.001). Although 16 institutions thought that the spasm provocation tests under the medications had some clinical usefulness of suppressing the next fatal arrhythmias, spasm provocation tests under the medication were performed in just 4 institutions. CONCLUSIONS: In the real world, there was no fundamental strategy for patients with ASCD due to coronary spasm. Each institution has each strategy for these patients. Cardiologists should have the same strategy and the same knowledge about ASCD patients due to coronary spasm in the future.
  • Satomi Yashima, Hiroyuki Takaoka, Togo Iwahana, Manami Takahashi, Yusuke Kondo, Hideki Ueda, Aya Saito, Yuya Ito, Noboru Motomura, Nobuyuki Hiruta, Jun-Ichiro Ikeda, Goro Matsumiya, Yoshio Kobayashi
    Internal medicine (Tokyo, Japan) 59(23) 3039-3044 2020年12月1日  
    We treated a man with co-incident Marfan-like connective tissue disease with morphologic left ventricular non-compaction (LVNC). He underwent valve-sparing aortic root replacement because of aortic root dilation at 43 years old. Pathological findings of the aorta revealed cystic medio-necrosis, consistent with Marfan syndrome. He developed congestive heart failure caused by LVNC at 47 years old. His daughter had scoliosis, and he had several physical characteristics suggestive of Marfan syndrome. We herein report a rare case of a patient who had Marfan-like connective disease with an LVNC appearance.
  • Makoto Sumazaki, Hideaki Shimada, Masaaki Ito, Fumiaki Shiratori, Eiichi Kobayashi, Yoichi Yoshida, Akihiko Adachi, Tomoo Matsutani, Yasuo Iwadate, Seiichiro Mine, Toshio Machida, Ikuo Kamitsukasa, Masahiro Mori, Kazuo Sugimoto, Akiyuki Uzawa, Satoshi Kuwabara, Yoshio Kobayashi, Mikiko Ohno, Eiichiro Nishi, Yoshiro Maezawa, Minoru Takemoto, Koutaro Yokote, Hirotaka Takizawa, Koichi Kashiwado, Hideo Shin, Takashi Kishimoto, Kazuyuki Matsushita, Sohei Kobayashi, Rika Nakamura, Natsuko Shinmen, Hideyuki Kuroda, Xiao-Meng Zhang, Hao Wang, Ken-Ichiro Goto, Takaki Hiwasa
    Cancer science 111(12) 4453-4464 2020年12月  
    Some cancers are related to atherosclerotic diseases; therefore, these two types of disease may share some antibody biomarkers in common. To investigate this, a first screening of sera was performed from patients with esophageal squamous cell carcinoma (ESCC) or acute ischemic stroke (AIS) for serological identification of antigens using recombinant cDNA expression cloning (SEREX). The amplified luminescent proximity homogeneous assay-linked immunosorbent assay (AlphaLISA) method, which incorporates glutathione donor beads and anti-human IgG acceptor beads, was used to evaluate serum antibody levels. SEREX screening identified low-density lipoprotein receptor-related protein-associated protein 1 (LRPAP1) as a target antigen of serum IgG antibodies in the sera of patients with ESCC or AIS. Antigens, including recombinant glutathione S-transferase-fused LRPAP1 protein, were prepared to examine serum antibody levels. AlphaLISA revealed significantly higher antibody levels against the LRPAP1 protein in patients with solid cancers such as ESCC and colorectal carcinoma and some atherosclerosis-related diseases such as AIS and diabetes mellitus compared with healthy donors. Correlation analysis revealed that the elevated serum antibody levels against LRPAP1 were associated with smoking, a well-known risk factor for both cancer and atherosclerosis. Serum LRPAP1 antibody is therefore a common marker for the early diagnosis of some cancers and atherosclerotic diseases and may reflect diseases caused by habitual smoking.
  • 庭野 亜美, 佐々木 晴香, 江口 紀子, 鎌田 知子, 川崎 健治, 渡辺 弘之, 小林 欣夫, 松下 一之
    超音波医学 47(Suppl.) S217-S217 2020年11月  
  • 與子田 一輝, 佐々木 晴香, 江口 紀子, 鎌田 知子, 川崎 健治, 渡辺 弘之, 松宮 護郎, 小林 欣夫, 松下 一之
    超音波医学 47(Suppl.) S241-S241 2020年11月  
  • 阿部 衣里子, 佐々木 晴香, 江口 紀子, 谷 明子, 北原 秀喜, 松浦 馨, 渡辺 弘之, 小林 欣夫, 松宮 護郎, 松下 一之
    超音波医学 47(Suppl.) S259-S259 2020年11月  
  • Ryo Ito, Takatsugu Kajiyama, Yusuke Kondo, Masahiro Nakano, Yoshio Kobayashi
    HeartRhythm case reports 6(11) 827-830 2020年11月  査読有り
  • Haruhiro Takahira, Kazuo Miyazawa, Takatsugu Kajiyama, Masahiro Nakano, Yusuke Kondo, Yoshio Kobayashi
    HeartRhythm case reports 6(11) 823-826 2020年11月  査読有り
  • 富岡 宏太朗, 船橋 伸禎, 田邉 信宏, 小澤 公哉, 巽 浩一郎, 小林 欣夫
    日本内科学会関東地方会 663回 24-24 2020年10月  
  • 小野 仁, 近藤 祐介, 細谷 裕一, 北川 真理, 高平 青洋, 伊藤 竜, 林 智彦, 仲野 美代, 宮澤 一雄, 梶山 貴嗣, 中野 正博, 小林 欣夫
    心臓 52(10) 1145-1152 2020年10月  
    植込み型除細動器(implantable cardioverter-defibrillator:ICD)は心室細動(ventricular fibrillation;VF)などの致死的不整脈に対する有効な治療法であるが、ICDによる不適切作動が生命予後の悪化につながるという報告がされている。不適切作動の原因として心房細動(atrial fibrillation;AF)が知られているが、AFの心拍数や持続時間を用いて、VF検出のための設定心拍数(VF検出ゾーン)の設定を考慮することに注目した報告はない。今回、ICD症例においてAFによる不適切作動のリスク因子について検討した。当院で遠隔モニタリングシステムを利用している403人を対象に、AFが記録された80人(19.8%)をAFによる不適切作動あり群となし群に分けて比較した。AFによる不適切作動あり群では、左房径が大きく、以前に12誘導心電図でAFが記録された症例やシングルチャンバーICDの症例が多かった。デバイスで記録されたAFの最大心拍数や平均心拍数、AF時間の割合は不適切作動あり群で高く、またデバイスにおけるVF検出レートとAFの最大心拍数との差であるminimum marginおよび平均心拍数との差であるaverage marginは、不適切作動あり群で小さかった。多変量解析を行うと、シングルチャンバーICDとaverage marginは、AFによる不適切作動の独立したリスク因子であった。さらに、average marginはカットオフ値を21bpmとすることで、リスク層別化が可能であった。AFによる不適切作動のリスク因子として、average marginは有用な指標であり、21bpm以下となる場合には積極的なAF治療を検討する必要がある。(著者抄録)
  • Yuichi Saito, Hideki Kitahara, Toshihiro Shoji, Takashi Nakayama, Yoshihide Fujimoto, Yoshio Kobayashi
    Heart, lung & circulation 29(10) 1511-1516 2020年10月  
    BACKGROUND: Autonomic nerve system and endothelial function play important roles in vasospastic angina. Elevated heart rate (HR), blood pressure (BP), and double product (DP) can increase endothelial-dependent coronary artery dilation and blood flow. However, the impact of HR, BP, and DP on occurrence and severity of VSA in the clinical setting is unclear. METHOD: A total of 170 patients undergoing intracoronary acetylcholine (ACh) provocation test during hospitalisation was included. Resting HR, BP, and DP were measured at least four times, and their variabilities were evaluated by standard deviations (SD) and coefficient of variations (CVs). Angiographic coronary artery vasospasm was defined as total or subtotal occlusion induced by ACh provocation. RESULTS: Mean±SD HR (65.7±9.1 vs 69.6±7.9 beats per minute; p=0.003), systolic BP (122.3±13.4 vs 127.7±14.6 mmHg; p=0.01), and DP (8,001±1,229 vs 8,903±1,495; p<0.001) were significantly lower in patients with a positive ACh test than the counterpart, whereas SD and CV of both HR and systolic BP were not significantly different between the two groups. Mean HR, BP, and DP progressively decreased with increase in the number of vessels with angiographic vasospasm. Multivariate analysis showed current smoking and lower DP as independent predictors of the greater number of vessels with provoked angiographic vasospasm. CONCLUSIONS: Resting HR, BP, and DP were lower in patients with vasospastic angina, especially in those with severe vasospasm.
  • Yoshiaki Kawase, Hitoshi Matsuo, Takashi Akasaka, Yasutsugu Shiono, Nobuhiro Tanaka, Tetsuya Amano, Ken Kozuma, Masato Nakamura, Hiroyoshi Yokoi, Yoshio Kobayashi, Yuji Ikari
    Cardiovascular intervention and therapeutics 35(4) 425-425 2020年10月  
    In the original publication of the article, author group affiliation was published incorrectly. The correct affiliation for author group is given in this correction.
  • Takahiro Kobayashi, Hiroyuki Takaoka, Haruka Sasaki, Manami Takahashi, Kan Saito, Tomohiko Hayashi, Kwangho Lee, Yoshihide Fujimoto, Masato Yamanouchi, Yoshio Kobayashi
    JACC. Case reports 2(12) 1917-1922 2020年10月  
    We report the case of a 70-year-old woman with hypertrophic obstructive cardiomyopathy, who was admitted because of severe heart failure and cardiogenic shock and mechanical support requiring extracorporeal membrane oxygenation. She recovered well by percutaneous transluminal septal myocardial ablation under the extracorporeal membrane oxygenation support and was discharged without complications. (Level of Difficulty: Advanced.).
  • Masahiro Nakano, Yusuke Kondo, Takatsugu Kajiyama, Kazuo Miyazawa, Miyo Nakano, Tomohiko Hayashi, Ryo Ito, Haruhiro Takahira, Mari Kitagawa, Yoshio Kobayashi
    Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing 59(1) 43-48 2020年10月  査読有り
    PURPOSE: The classification using QRS morphology of V1 lead is a useful simple predictor of accessory pathway location (type A, R or Rs pattern; type B, rS pattern; type C, QS or Qr pattern), but often leads to misdiagnosis of accessory pathway location, especially in types B and C. The synthesized 18-lead electrocardiography (ECG) derived from standard 12-lead ECG can provide virtual waveforms of right-sided chest leads. This study aimed to evaluate the usefulness of the right-sided chest lead ECG for prediction of accessory pathway location. METHODS: This retrospective study included 44 patients in whom successful ablation of manifest Wolff-Parkinson-White (WPW) syndrome was performed. Synthesized ECG waveforms were automatically generated, and ECG data obtained before the procedure. RESULTS: There were 26, 4, and 14 patients with left, right, and septal accessory pathways, respectively. All left accessory pathway cases have type A in V1 and syn-V4R leads. Of the 4 right accessory pathway cases, 2 have type B in V1 and syn-V4R leads. Other 2 of 4 cases have type C. In V1 lead, 5 of 14 septal accessory pathway cases have type C, 7 of 14 cases have type B, and 2 of 14cases have type A. In syn-V4R lead, all 14 septal accessory pathway cases have type C. The QRS morphology of V1 and syn-V4 leads could predict the site of accessory pathway with overall accuracy of 79% and 95%, respectively. CONCLUSIONS: QRS morphology of syn-V4R lead may be useful for predicting accessory pathway location of manifest WPW syndrome.
  • Ryohei Ono, Togo Iwahana, Yoshio Kobayashi
    BMJ case reports 13(9) 2020年9月23日  
  • L Christian Napp, Victoria L Cammann, Milosz Jaguszewski, Konrad A Szawan, Manfred Wischnewsky, Sebastiano Gili, Maike Knorr, Susanne Heiner, Rodolfo Citro, Eduardo Bossone, Fabrizio D'Ascenzo, Michael Neuhaus, Jennifer Franke, Ioana Sorici-Barb, Michel Noutsias, Christof Burgdorf, Wolfgang Koenig, Behrouz Kherad, Annahita Sarcon, Lawrence Rajan, Guido Michels, Roman Pfister, Alessandro Cuneo, Claudius Jacobshagen, Mahir Karakas, Alexander Pott, Philippe Meyer, Jose D Arroja, Adrian Banning, Florim Cuculi, Richard Kobza, Thomas A Fischer, Tuija Vasankari, K E Juhani Airaksinen, Christian Hauck, Carla Paolini, Claudio Bilato, Yoichi Imori, Ken Kato, Yoshio Kobayashi, Grzegorz Opolski, Monika Budnik, Rafal Dworakowski, Philip MacCarthy, Christoph Kaiser, Stefan Osswald, Leonarda Galiuto, Wolfgang Dichtl, Christina Chan, Paul Bridgman, Daniel Beug, Clément Delmas, Olivier Lairez, Ibrahim El-Battrawy, Ibrahim Akin, Ekaterina Gilyarova, Alexandra Shilova, Mikhail Gilyarov, John D Horowitz, Karolina Polednikova, Petr Tousek, Petr Widimský, David E Winchester, Jan Galuszka, Christian Ukena, Gregor Poglajen, Pedro Carrilho-Ferreira, Carlo Di Mario, Abhiram Prasad, Charanjit S Rihal, P Christian Schulze, Matteo Bianco, Filippo Crea, Martin Borggrefe, Lars S Maier, Fausto J Pinto, Ruediger C Braun-Dullaeus, Wolfgang Rottbauer, Hugo A Katus, Gerd Hasenfuß, Carsten Tschöpe, Burkert M Pieske, Holger Thiele, Heribert Schunkert, Michael Böhm, Stephan B Felix, Thomas Münzel, Jeroen J Bax, Johann Bauersachs, Eugene Braunwald, Thomas F Lüscher, Frank Ruschitzka, Jelena R Ghadri, Christian Templin
    European heart journal 41(34) 3255-3268 2020年9月7日  
    AIMS: Takotsubo syndrome (TTS) is an acute heart failure syndrome, which shares many features with acute coronary syndrome (ACS). Although TTS was initially described with angiographically normal coronary arteries, smaller studies recently indicated a potential coexistence of coronary artery disease (CAD) in TTS patients. This study aimed to determine the coexistence, features, and prognostic role of CAD in a large cohort of patients with TTS. METHODS AND RESULTS: Coronary anatomy and CAD were studied in patients diagnosed with TTS. Inclusion criteria were compliance with the International Takotsubo Diagnostic Criteria for TTS, and availability of original coronary angiographies with ventriculography performed during the acute phase. Exclusion criteria were missing views, poor quality of angiography loops, and angiography without ventriculography. A total of 1016 TTS patients were studied. Of those, 23.0% had obstructive CAD, 41.2% had non-obstructive CAD, and 35.7% had angiographically normal coronary arteries. A total of 47 patients (4.6%) underwent percutaneous coronary intervention, and 3 patients had acute and 8 had chronic coronary artery occlusion concomitant with TTS, respectively. The presence of CAD was associated with increased incidence of shock, ventilation, and death from any cause. After adjusting for confounders, the presence of obstructive CAD was associated with mortality at 30 days. Takotsubo syndrome patients with obstructive CAD were at comparable risk for shock and death and nearly at twice the risk for ventilation compared to an age- and sex-matched ACS cohort. CONCLUSIONS: Coronary artery disease frequently coexists in TTS patients, presents with the whole spectrum of coronary pathology including acute coronary occlusion, and is associated with adverse outcome. TRIAL REGISTRATION: ClinicalTrials.gov number: NCT01947621.
  • Yuichi Saito, Hideki Kitahara, Takeshi Nishi, Yoshihide Fujimoto, Yoshio Kobayashi
    Coronary artery disease 31(6) 565-566 2020年9月  
  • Hiroyuki Takaoka, Masae Uehara, Yuichi Saito, Joji Ota, Yasunori Iida, Manami Takahashi, Koichi Sano, Issei Komuro, Yoshio Kobayashi
    Internal medicine (Tokyo, Japan) 59(17) 2095-2103 2020年9月1日  
    Objective Forward-projected Model-based Iterative Reconstruction SoluTion (FIRST) is a novel reconstruction method. We investigated the improvement in the diagnostic performance for the detection of abnormal late enhancement (LE) in left ventricular myocardium (LVM) using a new-generation 320-slice computed tomography (CT) device with FIRST. Methods This is a retrospective study that included 100 adult patients who underwent cardiac CT including a late phase scan and magnetic resonance imaging (MRI) within 3 months. The first 50 consecutive patients (first-generation group) underwent first-generation 320-slice CT without FIRST, and the next 50 consecutive patients (second-generation group) underwent second-generation 320-slice CT with FIRST. We compared the diagnostic performance of the first- and second-generation 320-slice CT with FIRST with MRI as a reference standard to detect LE in LVM. Results In the patient-based analysis, the sensitivity, specificity, positive predictive value, negative predictive value, and overall accuracy of detection of LE on CT were 79%, 90%, 92%, 76%, and 84%, respectively, in the first-generation group and 97%, 84%, 91%, 94%, and 92%, respectively, in the second-generation group. The sensitivity was significantly higher in the second-generation group than in the first-generation group (p=0.049). In the segment-based analysis, the sensitivity, specificity, positive predictive value, negative predictive value, and overall accuracy of detection of LE on CT were 69%, 96%, 83%, 92%, and 90%, respectively, in the first-generation group and 87%, 94%, 84%, 95%, and 92%, respectively, in the second-generation group. The sensitivity and negative predictive value were significantly higher in the second-generation group than in the first-generation group (p<0.001 and p=0.016). The contrast-noise ratio was significantly higher in the second-generation group than in the first-generation group (5.6±1.7 vs. 2.8±1.1, p<0.001), and the radiation dose for the assessment of LE on CT was significantly higher in the first-generation group than in the second-generation group (4.7±2.7 mSv vs. 2.3±0.1 mSv, p<0.001). Conclusion The diagnostic performance for the detection of LE in LVM significantly improved with the use of second-generation 320-slice CT and FIRST.
  • Yuichi Saito, Toshihiro Shoji, Kazuya Tateishi, Hideki Kitahara, Yoshihide Fujimoto, Yoshio Kobayashi
    Advances in therapy 37(9) 3807-3815 2020年9月  
    BACKGROUND: Previous studies showed the relation of mental distress such as anxiety and depression to coronary vasoconstriction and myocardial ischemia. However, the mental health status of patients suspected to have vasospastic angina is unclear. METHODS: A total of 99 patients underwent intracoronary acetylcholine (ACh) provocation tests for the diagnosis of vasospastic angina and mental health assessment using the 12-item General Health Questionnaire (GHQ-12) and State-Trait Anxiety Inventory Form Y (STAI Y-2). Patients with binary GHQ-12 ≥ 4 were defined as having poor mental health. RESULTS: Median GHQ-12 and STAI Y-2 were 3 [1, 6] and 44 [36, 50]. Forty-one (41%) patients had binary GHQ-12 ≥ 4, and 48 (48%) had positive ACh provocation tests. The number of provoked vasospasms and rate of electrocardiographic change and chest pain during ACh tests were not significantly different between patients with and without GHQ-12 ≥ 4. The incidence of positive ACh provocation test was similar between the two groups (49% vs. 48%, p = 1.00). The multivariable analysis indicated that younger age, no history of percutaneous coronary intervention and no diabetes mellitus were factors associated with higher GHQ-12 and/or STAI Y-2 scores. CONCLUSIONS: More than 40% of patients who underwent ACh provocation tests had poor mental condition. No impact of mental distress on positive ACh tests was found in this study.
  • Sho Okada, Togo Iwahana, Yoshio Kobayashi
    Circulation journal : official journal of the Japanese Circulation Society 84(9) 1673-1674 2020年8月25日  
  • Yuuki Shimizu, Kazuhisa Kondo, Yoshihiro Fukumoto, Masayuki Takamura, Teruo Inoue, Tokuichiro Nagata, Yoshihiro J Akashi, Yoshihiro Yamada, Koichiro Kuwahara, Yoshio Kobayashi, Rei Shibata, Toyoaki Murohara
    Circulation reports 2(9) 531-535 2020年8月8日  
    Background: Despite the growing knowledge regarding optimal treatments for critical limb ischemia (CLI), there are still a considerable number of patients who have to undergo major limb amputation. Intramuscular injection of autologous adipose-derived regenerative cells (ADRCs) in these patients has shown therapeutic potential in improving tissue ischemia, in both preclinical and initial pilot studies. Here, we present a clinical protocol for ADRCs use in a multicenter trial. Methods and Results: The TACT-ADRC multicenter trial is a prospective, interventional, single-arm, open-labeled study at 8 hospitals in Japan, investigating the safety and feasibility of intramuscular injections of ADRCs and testing the hypothesis that this treatment promotes neovascularization and improves major amputation-free survival rates in patients with CLI who have no other treatment option. 40 patients with CLI will be enrolled and followed up from November 2015 to November 2020. Freshly isolated autologous ADRCs will be injected into the target ischemic limbs. Survival rate, adverse events, major limb amputation, ulcer size, 6-min walking distance, numerical rating scale, ankle-brachial pressure index, skin perfusion pressure and digital subtraction angiography will be evaluated at baseline and during 6 months' follow-up. Conclusions: This trial will demonstrate whether implantation of autologous ADRCs is a safe and effective method for therapeutic angiogenesis, resulting in an improvement in major amputation-free survival rates in patients with CLI.
  • Yusuke Kondo, Masahiro Nakano, Takatsugu Kajiyama, Miyo Nakano, Tomohiko Hayashi, Ryo Ito, Haruhiro Takahira, Yoshio Kobayashi
    Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing 58(2) 133-139 2020年8月  査読有り
    BACKGROUND: Leads are often considered the weakest link in implantable cardioverter-defibrillator (ICD) systems, and lead dysfunction is a major concern for ICD recipients. The aim of this study was to compare the lead performance from three different manufacturers. METHODS: We retrospectively reviewed consecutive patients who underwent ICD system implantation at Chiba University Hospital, Japan, between March 2008 and September 2017. The following leads were implanted in our center: Durata (St. Jude Medical, St. Paul, MN, USA, now Abbott) (n = 105), Linox and LinoxSmart (Biotronik, Berlin, Germany) (n = 66), and Sprint Quattro (Medtronic, Minneapolis, MN, USA) (n = 126). RESULTS: A total of 297 ICD leads were analyzed. Failure rates for Durata, Linox/LinoxSmart, and Sprint Quattro were 0.20%/patient year, 0.95%/patient year, and 1.84%/patient year, respectively, during a mean follow-up of 4.8, 6.4, and 3.0 years, respectively. The cumulative ICD lead survival probability was 98.9%, 100%, and 87.5%, after 5 years, respectively. The survival probability over the entire follow-up time as measured by the log-rank test was lower for Sprint Quattro leads than for either Durata (p = 0.011) or Linox/LinoxSmart (p = 0.028). The difference between Durata and Linox/LinoxSmart was not significant (p = 0.393). CONCLUSIONS: In this single-center retrospective study, the performance of Sprint Quattro was lower than the performance of Linox/LinoxSmart and Durata leads. Large-scale, multi-center studies or manufacturer-independent registries may be necessary to confirm or reject self-reported survival probabilities from manufacturers' product performance reports.
  • Li SY, Yoshida Y, Kobayashi E, Adachi A, Hirono S, Matsutani T, Mine S, Machida T, Ohno M, Nishi E, Maezawa Y, Takemoto M, Yokote K, Kitamura K, Hiwasa T
    International journal of molecular medicine 46(4) 1274-1288 2020年7月  
    The aim of the present study was to identify novel antibody markers for the early diagnosis of atherosclerosis in order to improve the prognosis of patients at risk for acute ischemic stroke (AIS) and acute myocardial infarction (AMI). A first screening involved the serological identification of antigens by recombinant cDNA expression cloning and identified additional sex combs‑like 2 (ASXL2) as a target antigen recognized by serum IgG antibodies in the sera of patients with atherosclerosis. Antigens, including the recombinant glutathione S‑transferase‑fused ASXL2 protein and its synthetic peptide were then prepared to examine serum antibody levels. Amplified luminescence proximity homogeneous assay‑linked immunosorbent assay, which incorporates glutathione‑donor beads and anti‑human‑IgG‑acceptor beads, revealed significantly higher serum antibody levels against the ASXL2 protein and its peptide in the patients with AIS, diabetes mellitus, AMI, chronic kidney disease, esophageal squamous cell carcinoma, or colorectal carcinoma compared with those in healthy donors. The ASXL2 antibody levels were well associated with hypertension complication, but not with sex, body mass index, habitual smoking, or alcohol intake. These results suggest that the serum ASXL2 antibody marker can discriminate between hypertension‑induced atherosclerotic AIS and AMI, as well as a number of digestive organ cancers.
  • 仲野 美代, 近藤 祐介, 中野 正博, 梶山 貴嗣, 宮澤 一雄, 林 智彦, 伊藤 竜, 高平 青洋, 小林 欣夫
    日本循環器学会学術集会抄録集 84回 OJ2-2 2020年7月  
  • 高平 青洋, 梶山 貴嗣, 近藤 祐介, 中野 正博, 宮澤 一雄, 仲野 美代, 林 智彦, 伊藤 竜, 北川 真理, 小林 欣夫
    日本循環器学会学術集会抄録集 84回 OJ16-1 2020年7月  
  • 小野 仁, 宮澤 一雄, 鳴海 頌子, 細谷 裕一, 北川 真理, 高平 青洋, 伊藤 竜, 林 智彦, 仲野 美代, 梶山 貴嗣, 中野 正博, 近藤 祐介, 小林 欣夫
    日本循環器学会学術集会抄録集 84回 CP6-1 2020年7月  
  • 細谷 裕一, 近藤 祐介, 小野 仁, 中野 正博, 梶山 貴嗣, 宮澤 一雄, 仲野 美代, 林 智彦, 伊藤 竜, 高平 青洋, 北川 真理, 小林 欣夫
    日本循環器学会学術集会抄録集 84回 CP6-2 2020年7月  
  • 後藤 宏樹, 高岡 浩之, 高橋 愛, 若林 慎一, 菅原 暢文, 石川 啓史, 金枝 朋宜, 大門 道子, 上田 希彦, 佐野 剛一, 小林 欣夫
    日本循環器学会学術集会抄録集 84回 PJ17-7 2020年7月  
  • Sugawara Masafumi, Takaoka Hiroyuki, Takahashi Manami, Kosuda Reika, Onagi Yuuki, Ota Joji, Wakabayashi Shinichi, Ishikawa Keishi, Kanaeda Tomonori, Ueda Marehiko, Sano Koichi, Kobayashi Yoshio
    日本循環器学会学術集会抄録集 84回 FRS8-4 2020年7月  

MISC

 395
  • Yuichi Saito, Yoshio Kobayashi, Kenichi Tsujita, Koichiro Kuwahara, Yuji Ikari, Hiroyuki Tsutsui, Koichiro Kinugawa, Ken Kozuma
    Circulation Journal 88(11) 1727-1736 2024年11月  
    In patients with acute myocardial infarction (MI), heart failure (HF) is one of the most common complications that is associated with a significant burden of mortality and healthcare resources. The clinical benefits of key HF drugs, the so-called “4 pillars” or “fantastic 4”, namely β-blockers, mineralocorticoid receptor antagonists, angiotensin receptor-neprilysin inhibitor, and sodium-glucose cotransporter 2 inhibitors, have been established in patients with HF with reduced ejection fraction, whereas the effects of these drugs are not comprehensively appreciated in patients with acute MI. This review summarizes current evidence on pharmacological and device-based interventions for preventing HF after acute MI.
  • Yoshiyasu Minami, Junya Ako, Kenichi Tsujita, Hiroyoshi Yokoi, Yuji Ikari, Yoshihiro Morino, Yoshio Kobayashi, Ken Kozuma
    Cardiovascular Intervention and Therapeutics 39(3) 223-233 2024年7月  
    Abstract: Non-culprit lesion-related coronary events are a significant concern in patients with coronary artery disease (CAD) undergoing coronary intervention. Since several studies using intra-coronary imaging modalities have reported a high prevalence of vulnerable plaques in non-culprit lesions at the initial coronary event, the immediate stabilization of these plaques by intensive pharmacological regimens may contribute to the reduction in the adverse events. Although current treatment guidelines recommend the titration of statin and other drugs to attain the treatment goal of low-density lipoprotein cholesterol (LDL-C) level in patients with CAD, the early prescription of strong LDL-C lowering drugs with more intensive regimen may further reduce the incidence of recurrent cardiovascular events. In fact, several studies with intensive regimen have demonstrated a higher percentage of patients with the attainment of LDL-C treatment goal in the early phase following discharge. In addition to many imaging studies showing plaque stabilization by LDL-C lowering drugs, several recent reports have shown the efficacy of early statin and proprotein convertase subtilisin/kexin type 9 inhibitors on the immediate stabilization of non-culprit coronary plaques. To raise awareness regarding this important concept of immediate plaque stabilization and subsequent reduction in the incidence of recurrent coronary events, the term ‘Drug Intervention’ has been introduced and gradually applied in the clinical field, although a clear definition is lacking. The main target of this concept is patients with acute coronary syndrome as a higher prevalence of vulnerable plaques in non-culprit lesions in addition to the worse clinical outcomes has been reported in recent imaging studies. In this article, we discuss the backgrounds and the concept of drug intervention. Graphical Abstract: (Figure presented.)
  • AOKI Shuhei, TAKAOKA Hiroyuki, KINOSHITA Makiko, YASHIMA Satomi, SUZUKI Katsuya, NISHIKAWA Yusei, NOGUCHI Yoshitada, YOSHIDA Kazuki, SASAKI Haruka, SUZUKI Noriko, KOBAYASHI Yoshio
    日本循環器学会学術集会(Web) 88th 2024年  
  • 與子田一輝, 與子田一輝, 佐々木晴香, 佐々木晴香, 佐々木晴香, 高岡浩之, 鎌田知子, 川崎健治, 江口紀子, 江口紀子, 江口紀子, 小林欣夫, 松下一之, 松下一之
    超音波医学 Supplement 51 2024年  
  • YASHIMA Satomi, TAKAOKA Hiroyuki, TAKAHASHI Manami, KINOSHITA Makiko, AOKI Shuhei, KOBAYASHI Yoshio
    日本循環器学会学術集会(Web) 87th 2023年  

共同研究・競争的資金等の研究課題

 6